A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence.
A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence.
复制标题
DOI：
10.1093/jnci/djn154
复制
发表时间：
2008-07-02
期刊：
影响因子：
--
通讯作者：
White E
中科院分区：
文献类型：
--
作者：
Asgari MM;Maruti SS;White E
实验室研究结果表明，非甾体抗炎药(NSAIDs)可能对黑色素瘤具有化学预防和治疗作用。然而，很少有已发表的流行病学研究研究非甾体抗炎药的使用与黑色素瘤风险之间的关系。在维生素和生活方式(VITAL)队列研究中，我们调查了63,809名男性和女性使用非类固醇抗炎药是否与黑色素瘤风险相关。参与者在基线问卷中自我报告了过去10年中非甾体抗炎药的使用情况(小剂量阿司匹林、常规或特效阿司匹林以及非阿司匹林非类固醇抗炎药)以及与他们的黑色素瘤危险因素相关的数据。在将VITAL数据库与NCI监测、流行病学和最终结果癌症登记联系起来后，截至2005年12月31日，发现了349名发生黑色素瘤的患者。COX回归模型被用来估计黑色素瘤的危险比(HR)和95%可信区间(CI)，根据非甾体抗炎药的使用情况按总使用量、使用时间和剂量(表示为过去10年的平均使用天数)进行分类。所有的统计检验都是双面的。在调整了黑色素瘤危险因素和非甾体类抗炎药的使用适应症后，未发现非类固醇抗炎药的使用与黑色素瘤风险之间的关联。当使用至少4d/wk与不使用相比，任何NSAID剂量(HR=1.12，95%CI=0.84至1.48)、除小剂量阿司匹林外的任何NSAID(HR=1.03，95%CI=0.74至1.43)、普通或超强阿司匹林(HR=1.10，95%CI=0.76至1.58)或非阿司匹林NSAIDs(HR=1.22，95%CI=0.75至1.99)均未发现黑色素瘤风险降低。此外，NSAID的使用与肿瘤侵袭(P交互作用=.38)、肿瘤厚度(P趋势=.98)或转移风险(HR=1.09，95%CI=0.32至3.62)无关。非甾体抗炎药似乎不是黑色素瘤化学预防的好候选药物。
Results of laboratory studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) may have chemopreventive activity and therapeutic efficacy against melanoma. However, few published epidemiological studies have examined the association between NSAID use and melanoma risk. We examined whether NSAID use was associated with melanoma risk among 63 809 men and women in the Vitamins and Lifestyle (VITAL) cohort study. Participants self-reported NSAID use (low-dose aspirin, regular or extra-strength aspirin, and nonaspirin NSAIDs) during the previous 10 years and data related to their melanoma risk factors on a baseline questionnaire. After linkage of the VITAL database to the NCI Surveillance, Epidemiology, and End Results cancer registry, 349 patients with incident melanoma were identified through December 31, 2005. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of melanoma by NSAID use as categorized by overall use, duration of use, and dose (expressed as average number of days of use during the past 10 years). All statistical tests were two-sided. After adjusting for melanoma risk factors and indications for NSAID use, no association between NSAID use and melanoma risk was found. When use of at least 4 d/wk was compared with nonuse, no melanoma risk reduction was detected for any NSAID dose (HR = 1.12, 95% CI = 0.84 to 1.48), for any NSAID excluding low-dose aspirin (HR = 1.03, 95% CI = 0.74 to 1.43), for regular- or extra-strength aspirin (HR = 1.10, 95% CI = 0.76 to 1.58), or for nonaspirin NSAIDs (HR = 1.22, 95% CI = 0.75 to 1.99). Moreover, NSAID use was not associated with tumor invasion (Pinteraction = .38), tumor thickness (Ptrend = .98), or risk of metastasis (HR = 1.09, 95% CI = 0.32 to 3.62). NSAIDs do not appear to be good candidates for the chemoprevention of melanoma.
登录
查看更多内容
影响因子：
2.4
作者：
Ramirez, CC;Ma, FC;Kirsner, RS
通讯作者：
Kirsner, RS
影响因子：
2.4
作者：
Wilson, Kenneth S.
通讯作者：
Wilson, Kenneth S.
影响因子：
5
作者：
White, E;Patterson, RE;Potter, JD
通讯作者：
Potter, JD
影响因子：
10.3
作者：
Bardia, Aditya;Ebbert, Jon O.;Cerhan, James R.
通讯作者：
Cerhan, James R.
影响因子：
10.3
作者：
Jacobs, Eric J.;Thun, Michael J.;Calle, Eugenia E.
通讯作者：
Calle, Eugenia E.